SCHEMBL5877045

SCHEMBL5877045

COc1ccc([C@H](C=O)c2ccccc2)cc1OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.53
TDP1 Q9NUW8 1/20 0.53
MAPT P10636 2/20 0.49
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
ACHE P22303 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP1A1 P04798 1/20 0.45
CYP1B1 Q16678 1/20 0.45
ALDH1A1 P00352 2/20 0.44
TSHR P16473 1/20 0.44
GAA P10253 2/20 0.43
TTR P02766 1/20 0.43
TNF P01375 1/20 0.43
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 1/20 0.42
TDP2 O95551 1/20 0.42
HPGD P15428 1/20 0.42
MEN1 O00255 1/20 0.42
CA1 P00915 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1515750 1.00 L3MBTL1 (0.53) L3MBTL1TDP1MAPTCRHBPCRHR2
SCHEMBL1515708 0.86 LMNA (0.44) L3MBTL1TDP1MAPTCRHBPCRHR2
SCHEMBL5898854 0.86 TUBB1 (0.49) L3MBTL1TDP1MAPTCYP1A2ALDH1A1
SCHEMBL4970533 0.86 SMN1; SMN2 (0.40) L3MBTL1TDP1MAPTCRHBPCRHR2
SCHEMBL6508159 0.84 ALDH1A1 (0.47) L3MBTL1MAPTACHECYP1A2CYP1A1
SCHEMBL8501757 0.83 TDP1 (0.53) L3MBTL1TDP1MAPTCRHBPCRHR2
SCHEMBL6506655 0.82 PDE4D (0.48) L3MBTL1CYP1A2CYP1A1CYP1B1ALDH1A1
SCHEMBL3944811 0.82 NQO2 (0.46) L3MBTL1ACHECYP1A2CYP1A1CYP1B1
SCHEMBL6989802 0.81 AKR1C3 (0.44) L3MBTL1MAPTACHECYP1A2ALDH1A1
SCHEMBL4684702 0.80 ACHE (0.45) L3MBTL1TDP1MAPTACHECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed
EP-1414805-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY Aventis Pharma S.A. (FR) 2004-05-06 EP disclosed
WO-2003011833-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY AVENTIS PHARMA S.A. (FR) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT L3MBTL1 3963/4885TDP1 1752/4885MAPT 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.